Genes
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
85,013 comparisons from ClinicalTrials.gov.
Most participants first33,758 with no events in either group come last3,461 to 3,480 of 85,013
| Comparison | With the outcome | Risk difference, 95% interval | Participants | Trial |
|---|---|---|---|---|
| Azithromycin vs Placebo: Participants With Endometritis and/or Wound Infection and/or Other Post-cesarean Infections (Occurring Within 6 Weeks of Delivery) | 62 of 1,018 119 of 992 | -5.9 points -8.4 to -3.4 | 2,010 | NCT01235546 Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection |
| Placebo and Standard of Care vs Azithromycin and Standard of Care: Infant Pyloric Stenosis | 1 of 992 2 of 1,018 | -0.1 points -0.6 to 0.4 | 2,010 | NCT01235546 Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection |
| Placebo and Standard of Care vs Azithromycin and Standard of Care: Maternal Postpartum Readmission or Unscheduled Visit | 123 of 992 83 of 1,018 | 4.2 points 1.6 to 6.9 | 2,010 | NCT01235546 Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection |
| Placebo With Standard Prophylaxis vs Azithromycin (Zithromax) With Standard Prophylaxis: Maternal Fever | 81 of 992 51 of 1,018 | 3.2 points 1.0 to 5.4 | 2,010 | NCT01235546 Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection |
| Placebo and Standard of Care vs Azithromycin and Standard of Care: Neonatal Intensive Care Unit (NICU) Admission | 169 of 992 171 of 1,018 | 0.2 points -3.0 to 3.5 | 2,010 | NCT01235546 Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection |
| Placebo and Standard of Care vs Azithromycin and Standard of Care: serious adverse events | 29 of 992 15 of 1,018 | 1.4 points 0.2 to 2.8 | 2,010 | NCT01235546 Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection |
| Provision of Multiple Self-tests vs Referral Vouchers for VCT: deaths from any cause | 1 of 1,019 1 of 991 | -0.0 points -0.5 to 0.5 | 2,010 | NCT03135067 Secondary Distribution of HIV Self-tests: an Innovative Strategy for Promoting Partner Testing and Reducing HIV Risk |
| Absorb BVS vs XIENCE: deaths from any cause | 85 of 1,322 44 of 686 | 0.0 points -2.4 to 2.2 | 2,008 | NCT01751906 ABSORB III Randomized Controlled Trial (RCT) |
| Absorb BVS vs XIENCE: serious adverse events | 801 of 1,322 398 of 686 | 2.6 points -1.9 to 7.1 | 2,008 | NCT01751906 ABSORB III Randomized Controlled Trial (RCT) |
| Information vs Usual Care: Do-Not-Resuscitate | 136 of 1,011 144 of 997 | -1.0 points -4.0 to 2.0 | 2,008 | NCT04852055 Effect of an Advance Care Planning Intervention |
| Information vs Usual Care: Do-Not-Hospitalize | 31 of 1,011 35 of 997 | -0.4 points -2.1 to 1.1 | 2,008 | NCT04852055 Effect of an Advance Care Planning Intervention |
| Neoadjuvant TAS 2 Months Before and During RT vs Radiation Therapy Alone: serious adverse events | 33 of 1,003 16 of 1,003 | 1.7 points 0.3 to 3.1 | 2,006 | NCT00002597 Radiation Therapy With or Without Antiandrogen Therapy in Treating Patients With Stage I or Stage II Prostate Cancer |
| ChimeriVax™-JE 4 log10 PFU Vaccine vs Placebo: serious adverse events | 5 of 1,601 2 of 403 | -0.2 points -1.5 to 0.4 | 2,004 | NCT00314132 Safety Study of ChimeriVax™-JE Vaccine to Prevent Japanese Encephalitis. |
| Guardant Shield Blood Test vs Standard of Care: Assess Colorectal Cancer Screening Completion | 305 of 1,001 130 of 1,003 | 17.5 points 14.0 to 21.0 | 2,004 | NCT05987709 Study of Colorectal Cancer Screening Options |
| 20mcg Recombinant HEV vs Placebo: deaths from any cause | 6 of 1,000 1 of 1,000 | 0.5 points -0.1 to 1.2 | 2,000 | NCT00287469 A Safety and Efficacy Study of the Hepatitis E Vaccine in Nepal. |
| 20mcg Recombinant HEV vs Placebo: serious adverse events | 143 of 1,000 200 of 1,000 | -5.7 points -9.0 to -2.4 | 2,000 | NCT00287469 A Safety and Efficacy Study of the Hepatitis E Vaccine in Nepal. |
| Screening Group vs No Screening: Number of Participants With an Advance Directive at 12 Months | 653 of 992 644 of 1,008 | 1.9 points -2.2 to 6.1 | 2,000 | NCT01699503 Indiana University Dementia Screening Trial |
| PLWHIV and Mpox Coinfection vs HIV Negative PrEP Users With Mpox Infection: serious adverse events | 57 of 946 38 of 1,054 | 2.4 points 0.5 to 4.4 | 2,000 | NCT05965427 Morbidity, Mortality And Risk Factors of Mpox in HIV Negative High Risk Sexual Health Clinic Attenders and People Living With HIV |
| Human Rotavirus (HRV) Group vs HRV Porcine Circovirus (PCV)-Free Group: Number of Participants Reporting Serious Adverse Events (SAEs) | 251 of 998 262 of 1,002 | -1.0 points -4.8 to 2.8 | 2,000 | NCT06025695 Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks |
| Human Rotavirus (HRV) Group vs HRV Porcine Circovirus (PCV)-Free Group: deaths from any cause | 1 of 998 0 of 1,002 | 0.1 points -0.3 to 0.6 | 2,000 | NCT06025695 Immunogenicity, Reactogenicity and Safety of GlaxoSmithKline (GSK) Biologicals' Rotarix Porcine Circovirus (PCV)-Free Liquid Compared to Rotarix Liquid Given in 2-doses in Healthy Chinese Infants Starting at Age 6-16 Weeks |
Code
curl "https://conductscience.org/api/comparisons/v1?page=174"
Response
The first 2 of this page's 20 results. GET /api/comparisons/v1?page=174
{
"data": {
"total": 85013,
"results": [
{
"id": "NCT01235546-8c26fe85",
"title": "Azithromycin vs Placebo: Participants With Endometritis and/or Wound Infection and/or Other Post-cesarean Infections (Occurring Within 6 Weeks of Delivery)",
"summary": "62 of 1018 against 119 of 992; risk difference -5.9 points, 95% interval -8.4 to -3.4; NCT01235546, Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection",
"record": "/library/comparisons/NCT01235546-8c26fe85",
"nct_id": "NCT01235546",
"kind": "outcome",
"participants": 2010,
"risk_difference": {
"value": -0.05905594460992459,
"lower": -0.08440558029599159,
"upper": -0.03412829508385831
},
"group_1": "62 of 1,018",
"group_2": "119 of 992",
"difference": "-5.9 points",
"interval": "-8.4 to -3.4",
"trial_title": "Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection"
},
{
"id": "NCT01235546-8ecfb4a9",
"title": "Placebo and Standard of Care vs Azithromycin and Standard of Care: Infant Pyloric Stenosis",
"summary": "1 of 992 against 2 of 1018; risk difference -0.1 points, 95% interval -0.6 to 0.4; NCT01235546, Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection",
"record": "/library/comparisons/NCT01235546-8ecfb4a9",
"nct_id": "NCT01235546",
"kind": "outcome",
"participants": 2010,
"risk_difference": {
"value": -0.0009565720261106533,
"lower": -0.006193058943844927,
"upper": 0.0039355954277207165
},
"group_1": "1 of 992",
"group_2": "2 of 1,018",
"difference": "-0.1 points",
"interval": "-0.6 to 0.4",
"trial_title": "Study of Effectiveness and Safety of Azithromycin-based Extended-spectrum Prophylaxis to Prevent Post Cesarean Infection"
}
],
"no_events": 33758,
"columns": [
{
"key": "title",
"label": "Comparison"
},
{
"key": "group_1",
"label": "With the outcome",
"under": "group_2"
},
{
"key": "difference",
"label": "Risk difference, 95% interval",
"under": "interval"
},
{
"key": "participants",
"label": "Participants"
},
{
"key": "nct_id",
"label": "Trial",
"under": "trial_title"
}
],
"order": "Most participants first",
"kinds": {
"all": 85013,
"outcome": 33568,
"serious-adverse-events": 31897,
"deaths": 19548
}
},
"release": "trial-comparisons-2026-03-23-0.1.0",
"terms": [
{
"source": "ClinicalTrials.gov's posted results, through CTTI's AACT",
"license": "ClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "Freely available. Acknowledgement requested"
},
{
"source": "ClinicalTrials.gov",
"license": "none stated",
"notice": "ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.",
"short": "No license stated"
}
],
"next": "/api/comparisons/v1?page=175",
"request_id": "_A4ZhnomfwGdRT_h"
}Ask about these results. The first 10 go in the prompt.
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions. The measures are ConductScience's calculation from them.
NCBI Gene
One gene with its proteins, patents, drugs, trials, grants and papers.
ClinicalTrials.gov
Search clinical trials by condition, drug, outcome or NCT number, with the results each one posted.
Patent publications
Paste a sequence and see the patents that disclose it.
Opens sequences.conductscience.org
For software
Every answer on this page is also JSON, under /api/comparisons/v1. No key.
GET https://conductscience.org/api/comparisons/v1?q=placebo%20heart%20failure&kind=outcome
Ask an assistant